This is a short study, performed in different countries, to investigate how well one dose of mirabegron mirabegron suspension is taken, how long it stays in the body and how well it is tolerated in children aged 5 to less than 12 years with symptoms of overactive bladder (possibly caused by nerve dysfunction) The primary objective of the trial is to evaluate the pharmacokinetics (PK) of mirabegron oral suspension after single dose administration in children with neurogenic detrusor overactivity (NDO) or ov...

• Country None
• organs None
• Specialty None

PRE-transplant pharmacokinetics and Advagraf® Dosing In kidney transplant ReCipienTs Farmacocinética pre-trasplante y dosis de Advagraf® en receptores de trasplanate renal The primary objective of the study is to assess if Advagraf® pharmacokinetic parameters measured prior to transplantation can predict the dose required after transplantation to achieve target trough l...

• Country None
• organs None
• Specialty None

A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-center Dose Ranging Study with the Beta-3 AGONist YM178 in Patients with Symptomatic Overactive Bladder DRAGON To evaluate the dose-response relationship of YM178-OCAS on efficacy in patients with OAB.

• Country None
• organs None
• Specialty None

A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN A PROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS. Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4)) The primary objective of this study is to compare the four therapy regimens with regard to efficacy failure rate.

• Country None
• organs None
• Specialty None

A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects The objective of this study is to evaluate the safety and efficacy of ASP015K in moderate to severe Rheumatoid Arthritis (RA) subjects.

• Country None
• organs None
• Specialty None

A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and urinary Nerve Growth Factor in Female Subjects with Overactive Bladder and a Diagnosis of Detrusor Overactivity – A double-blind, randomized, placebo-controlled, parallel group, multicentre study 1. To evaluate the effect of solifenacin versus placebo on bladder wall thickness (BWT) after 12 weeks of treatment. 2. To evaluate the effect of solifenacin versus placebo on urinary Nerve Growth Fac...

• Country None
• organs None
• Specialty None

A study to provide access to continued treatment for subjects with prostate cancer who are currently participating in an enzalutamide clinical study The objective of the study is to provide access to continued treatment for subjects who are currently participating in an enzalutamide clinical study for their prostate cancer and who are continuing t...

• Country None
• organs None
• Specialty None

A study to evaluate efficacy and safety of ASP8232 as add-on therapy to the standard of care in patients with Type 2 Diabetes and Chronic Kidney Disease To evaluate the efficacy of ASP8232 in reducing Urinary Albumin to Creatinine Ratio (UACR) in subjects with Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) at 12 weeks compared to pl...

• Country None
• organs None
• Specialty None

Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2) The purpose of this study is to find the best possible (optimal) dose (effect versus adverse events) of YM150 to prevent the risk of blood clot formation after scheduled hip replacement su...

• Country None
• organs None
• Specialty None

Phase IIb, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12-Week Treatment with ASP1941 in Combination with Metformin in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone To evaluate the efficacy of a 12-week treatment of 4 doses of ASP1941 in combination with metformin compared to placebo in combination with metformin in subjects with Type 2 Diabetes Mellitus (T2DM) w...

• Country None
• organs None
• Specialty None